The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution
Open accessAbstract
Azithromycin (CP-62,993), a new acid-stable 15-membered-ring macrolide, was well absorbed following oral administration in mice, rats, dogs, and cynomolgus monkeys. This compound exhibited a uniformly long elimination half-life and was distributed exceptionally well into all tissues. This extravascular penetration of azithromycin was demonstrated by tissue/plasma area-under-the-curve ratios ranging from 13.6 to 137 compared with ratios for erythromycin of 3.1 to 11.6. The significance of these pharmacokinetic advantages of azithromycin over erythromycin was shown through efficacy in a series of animal infection models. Azithromycin was orally effective in treating middle ear infections induced in gerbils by transbulla challenges with amoxicillin-resistant Haemophilus influenzae or susceptible Streptococcus pneumoniae; erythromycin failed and cefaclor was only marginally active against the H. influenzae challenge. Azithromycin was equivalent to cefaclor and erythromycin against Streptococcus pneumoniae. In mouse models, the new macrolide was 10-fold more potent than erythromycin and four other antibiotics against an anaerobic infection produced by Fusobacterium necrophorum. Similarly, azithromycin was effective against established tissue infections induced by Salmonella enteritidis (liver and spleen) and Staphylococcus aureus (thigh muscle); erythromycin failed against both infections. The oral and subcutaneous activities of azithromycin, erythromycin, and cefaclor were similar against acute systemic infections produced by Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, or S. aureus, whereas azithromycin was more potent than erythromycin and cefaclor against the intracellular pathogen Listeria monocytogenes. The pharmacokinetic advantage of azithromycin over erythromycin in half-life was clearly demonstrated in prophylactic treatment of an acute mouse model of S. aureus infection. These properties of azithromycin strongly support the further evaluation of this new macrolide for use in community-acquired infections of skin or soft tissue and respiratory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE ROUTE OF ENTERIC INFECTION IN NORMAL MICE
Carter, P. B., & Collins, F. M. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.139.5.1189 · Cited by 664
Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., Borovoy, R., Brennan, L., & Mason, R. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1939 · Cited by 464
Self-citationAntibiotic entry into human polymorphonuclear leukocytes
Prokesch, R. C., & Hand, W. L. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.3.373 · Cited by 292
Microbioassay of Antimicrobial Agents
Simon, H. J., & Yin, E. J. (1970) · Applied Microbiology · doi:10.1128/aem.19.4.573-579.1970 · Cited by 203
WASHINGTON, J. A., & Wilson, W. R. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60322-x · Cited by 124
Klein, J. O. (1980) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894800890s326 · Cited by 94
Interspecies Correlation of the Pharmacokinetics of Erythromycin, Oleandomycin, and Tylosin
Duthu, G. S. (1985) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600740907 · Cited by 56
Pirbenicillin: Pharmacokinetic Parameters in Mice
English, A. R., GIRARD, D., & Retsema, J. A. (1976) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.10.3.491 · Cited by 22
Self-citation
Cited by
The Mycobacterium avium complex
Inderlied, C. B., Kemper, C. A., & Bermudez, L. E. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.3.266 · Cited by 687
Hicks, L. A., Bartoces, M. G., Roberts, R. M., Suda, K. J., Hunkler, R. J., Taylor, T. H., & Schrag, S. J. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ076 · Cited by 559
The macrolide antibiotic renaissance
Dinos, G. P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13936 · Cited by 471
Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., Borovoy, R., Brennan, L., & Mason, R. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1939 · Cited by 464
Self-citationA platform for the discovery of new macrolide antibiotics
Seiple, I. B., Zhang, Z., Jakubec, P., Langlois-Mercier, A., Wright, P. M., Hog, D. T., Yabu, K., Allu, S. R., Fukuzaki, T., Carlsen, P. N., et al. (2016) · Nature · doi:10.1038/nature17967 · Cited by 351
Havlir, D. V., Dubé, M. P., Sattler, F. R., Forthal, D. N., Kemper, C. A., Dunne, M. W., Parenti, D. M., Lavelle, J. P., White, A. C., Witt, M. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608083350604 · Cited by 329
Peters, D. H., Friedel, H. A., & McTavish, D. (1992) · Drugs · doi:10.2165/00003495-199244050-00007 · Cited by 304
Bergeron, J., Ammirati, M., Danley, D., James, L., Norcia, M., Retsema, J., Strick, C. A., Su, W. G., Sutcliffe, J., & Wondrack, L. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.9.2226 · Cited by 157
Azithromycin-resistant syphilis infection: San Francisco, California, 2000–2004.
Mitchell, S. J., Engelman, J., Kent, C. K., Lukehart, S. A., Godornes, C., & Klausner, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/498899 · Cited by 137
Metadata
- Authors
- Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A., Haskell, S. L., & Retsema, J. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1987-12
- Volume
- 31
- Issue
- 12
- Pages
- 1948-1954
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2132254727
- Cited by
- 321
- References
- 8
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.